Axoltis Pharma announces its participation in the BIO International Convention, taking place from June 22 to 25, 2026, at the San Diego Convention Center in San Diego, CA, United-States. The BIO International Convention is one of the world’s premier biotechnology partnering events, bringing together biotechnology companies, pharmaceutical leaders, investors, research institutions and innovation stakeholders from … Continued
We are pleased to announce Axoltis Pharma’s participation in the ENCALS 2026 Meeting and the TRICALS satellite meeting, which will take place from June 24–26, 2026, at the Palacio Municipal de Congresos in Madrid, Spain. ENCALS is the leading European scientific meeting dedicated to amyotrophic lateral sclerosis (ALS), bringing together clinicians, researchers, patient organizations and … Continued
Axoltis Pharma today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments. The funding, which includes new and historic investors, will enable the company to pursue the development of NX210c, its lead drug candidate, currently in phase 2 clinical trials in patients with ALS (Amyotrophic … Read more
Axoltis Pharma lance une campagne d’investissement participatif sur la plateforme Capital Cell. Cette opération s’inscrit dans un tour de financement destiné à accélérer le développement de NX210c, son candidat-médicament actuellement en fin de phase 2 d’essai clinique chez des patients atteints de sclérose latérale amyotrophique (SLA, ou maladie de Charcot). Communiqué de Presse
Axoltis Pharma is delighted to announce that the 𝗗𝗦𝗠𝗕 completed its first safety assessment of the Phase 2b trial in Amyotrophic Lateral Sclerosis (ALS) and 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗲𝗱 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗺𝗼𝗱𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻. 𝗦𝗘𝗔𝗟𝗦 is a multi-center, randomized, double-blind, placebo-controlled 𝗣𝗵𝗮𝘀𝗲 𝟮 𝘁𝗿𝗶𝗮𝗹, 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗻𝗴 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗮𝗻𝗱 𝘀𝗮𝗳𝗲𝘁𝘆 𝗼𝗳 𝗡𝗫𝟮𝟭𝟬𝗰. Up to 𝟭𝟲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻 𝘀𝗶𝘁𝗲𝘀 to … Read more
https://www.axoltis.com//home/neuronaxhb/axoltisv2/web/app/uploads/2025/01/France3Axoltis-new.mp4
Phase II clinical trial evaluating NX210c drug candidate efficacy in ALS patients (“SEALS”): rational and innovative design
Axoltis is a nominee in “Best Startup” category.